Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
Telomir Pharmaceuticals (NASDAQ:TELO) has been featured in a local ABC exclusive highlighting promising age reversal outcomes in two senior dogs using their novel small molecule, Telomir-1. The compassionate use program, observed by Dr. Michael Roizen, showed remarkable improvements in the dogs' health and vitality. Zeus, a 12-year-old German Shepherd, experienced complete remission of terminal cancer, while Benson, a 12-year-old Newfoundland with severe arthritis, regained mobility.
Erez Aminov, Telomir's new Chairman CEO, emphasized the company's commitment to advancing Telomir-1's research and accelerating its path to market. Dr. Roizen expressed excitement about Telomir-1's potential to promote cell regeneration and reverse aspects of aging by lengthening telomeres. The company aims to progress towards human trials for specific indications.
Telomir Pharmaceuticals (NASDAQ:TELO) è stata protagonista di un'esclusiva locale su ABC che mette in evidenza i promettenti risultati di reversibilità dell'età in due cani anziani grazie al loro nuovo piccolo composto, Telomir-1. Il programma di uso compassionevole, osservato dal Dr. Michael Roizen, ha mostrato miglioramenti straordinari nella salute e vitalità dei cani. Zeus, un pastore tedesco di 12 anni, ha vissuto una remissione completa di un cancro terminale, mentre Benson, un Terranova di 12 anni con grave artrite, ha riacquistato mobilità.
Erez Aminov, il nuovo CEO e presidente di Telomir, ha sottolineato l'impegno dell'azienda nell'avanzare la ricerca su Telomir-1 e accelerare il suo percorso verso il mercato. Il Dr. Roizen ha espresso entusiasmo per il potenziale di Telomir-1 di promuovere la rigenerazione cellulare e invertire aspetti dell'invecchiamento allungando i telomeri. L'azienda mira a procedere verso prove cliniche per indicazioni specifiche.
Telomir Pharmaceuticals (NASDAQ:TELO) ha sido destacada en una exclusiva local de ABC que pone de relieve los prometedores resultados de reversión de la edad en dos perros ancianos usando su novedosa molécula pequeña, Telomir-1. El programa de uso compasivo, observado por el Dr. Michael Roizen, mostró mejoras notables en la salud y vitalidad de los perros. Zeus, un pastor alemán de 12 años, experimentó una remisión completa de cáncer terminal, mientras que Benson, un Terranova de 12 años con artritis severa, recuperó la movilidad.
Erez Aminov, el nuevo CEO y presidente de Telomir, enfatizó el compromiso de la empresa por avanzar en la investigación de Telomir-1 y acelerar su camino al mercado. El Dr. Roizen expresó su entusiasmo por el potencial de Telomir-1 para promover la regeneración celular e invertir aspectos del envejecimiento al alargar los telómeros. La compañía aspira a avanzar hacia ensayos clínicos para indicaciones específicas.
텔로미어 제약(Telomir Pharmaceuticals, NASDAQ:TELO)은 ABC의 지역 독점 보도에서 두 마리의 노령견에 대한 노화 역전 결과를 강조했습니다. 이들은 그들의 새로운 소분자 텔로미어-1을 사용했습니다. 마이클 로이젠(Michael Roizen) 박사가 관찰한 연민적 사용 프로그램은 개들의 건강과 활력에서 놀라운 개선을 보여주었습니다. 12세 독일 셰퍼드인 제우스는 말기 암이 완전 관해되었고, 심한 관절염을 앓던 12세 뉴펀들랜드인 벤슨은 움직임을 회복했습니다.
텔로미어의 새로운 CEO 겸 회장인 에레즈 아미노프(Erez Aminov)는 텔로미어-1의 연구를 발전시키고 시장으로 가는 길을 가속화하겠다는 회사의 의지를 강조했습니다. 로이젠 박사는 텔로미어-1이 세포 재생을 촉진하고 텔로미어를 늘림으로써 노화의 측면을 역전시킬 수 있는 잠재력에 대해 기대감을 표명했습니다. 이 회사는 특정 적응증에 대한 인간 임상 시험으로 나아갈 계획입니다.
Telomir Pharmaceuticals (NASDAQ:TELO) a été présenté dans un exclusif local d'ABC mettant en avant des résultats prometteurs de réversion de l'âge chez deux chiens âgés utilisant leur nouvelle petite molécule, Telomir-1. Le programme d'utilisation compassionnelle, observé par le Dr. Michael Roizen, a montré des améliorations remarquables de la santé et de la vitalité des chiens. Zeus, un berger allemand de 12 ans, a connu une rémission complète d'un cancer terminal, tandis que Benson, un Terre-Neuve de 12 ans souffrant d'arthrite sévère, a retrouvé sa mobilité.
Erez Aminov, le nouveau PDG et président de Telomir, a souligné l'engagement de l'entreprise à faire progresser la recherche sur Telomir-1 et à accélérer son chemin vers le marché. Le Dr Roizen a exprimé son enthousiasme quant au potentiel de Telomir-1 pour promouvoir la régénération cellulaire et inverser certains aspects du vieillissement en allongeant les télomères. L'entreprise vise à progresser vers des essais cliniques pour des indications spécifiques.
Telomir Pharmaceuticals (NASDAQ:TELO) wurde in einem lokalen ABC-Bericht hervorgehoben, der vielversprechende Ergebnisse zur Altersumkehr bei zwei älteren Hunden mit ihrem neuartigen kleinen Molekül Telomir-1 präsentiert. Das Programm zur compassionaten Nutzung, das von Dr. Michael Roizen beobachtet wurde, zeigte bemerkenswerte Verbesserungen in der Gesundheit und Vitalität der Hunde. Zeus, ein 12-jähriger deutscher Schäferhund, erlebte eine vollständige Remission von terminalem Krebs, während Benson, ein 12-jähriger Neufundländer mit schwerer Arthritis, seine Mobilität zurückerlangte.
Erez Aminov, der neue CEO und Vorsitzende von Telomir, betonte das Engagement des Unternehmens, die Forschung zu Telomir-1 voranzutreiben und seinen Weg auf den Markt zu beschleunigen. Dr. Roizen äußerte sich begeistert über das Potenzial von Telomir-1, die Zellregeneration zu fördern und Aspekte des Alterns durch Verlängerung der Telomere umzukehren. Das Unternehmen strebt an, in Richtung klinischer Studien für spezifische Indikationen voranzuschreiten.
- Telomir-1 showed promising results in age reversal for two senior dogs
- Complete remission of terminal cancer observed in one dog
- Significant mobility improvement in a dog with severe arthritis
- Potential application of Telomir-1 for human longevity and age-related conditions
- Telomir-1 is still in pre-clinical stage
- Results are based on a small compassionate use program, not a full clinical trial
Insights
The preliminary results of Telomir-1 in dogs are intriguing but should be viewed cautiously. While the reported outcomes for Zeus and Benson are remarkable, it's important to note that this was a small compassionate use program, not a controlled clinical trial. The sample size of two dogs is extremely , making it premature to draw broad conclusions.
The potential for telomere lengthening to impact age-related conditions is a fascinating area of research. However, the leap from these anecdotal canine results to human applications is substantial. Investors should be aware that Telomir Pharmaceuticals is still in the pre-clinical stage and the path to human trials and potential FDA approval is long and uncertain.
While this news generates buzz, it's important to remember that many promising pre-clinical results fail to translate to human therapies. The company's focus on accelerating research is positive, but substantial scientific validation is still needed.
This news, while generating publicity, doesn't significantly alter Telomir Pharmaceuticals' financial outlook. As a pre-clinical stage company (NASDAQ:TELO), Telomir likely has no immediate revenue streams from Telomir-1. The path to commercialization is long and capital-intensive, requiring substantial investment in clinical trials and regulatory approvals.
Investors should focus on Telomir's cash position, burn rate and funding strategy to support the extensive research needed. The appointment of a new CEO, Erez Aminov, could signal a shift in company strategy or fundraising efforts, which may be more impactful than these early-stage results.
While positive press can boost investor sentiment short-term, long-term value will depend on clinical trial outcomes and the company's ability to navigate the regulatory landscape. The potential market for age-related therapies is vast, but competition in this space is also intense.
Promising results with Telomir-1 Demonstrates Potential in Promoting Life Quality and Longevity in Senior Dogs
TAMPA, FL / ACCESSWIRE / August 20, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, is proud to announce that its novel small molecule, Telomir-1, was recently featured in an exclusive local ABC television news segment highlighting promising "age reversal" outcomes in two senior dogs.
The use of Telomir-1 in these two dogs was observed by Telomir's special advisor Dr. Michael Roizen, the former Chief Wellness Officer of the Cleveland Clinic and a leader in age-related medicine. In this small compassionate use program, remarkable improvements in the health and vitality of the dogs after treatment with Telomir-1 was noted, offering a glimpse into the potential future applications for humans.
In the segment, "ABC7 Exclusive: New study reveals promising results for age reversal pill on dogs," the transformative potential of Telomir-1 was showcased through the stories of Zeus and Benson, two senior dogs from Donte's Den rescue organization in Myakka City, Florida. After being treated with Telomir-1, both dogs exhibited significant improvements in their health conditions. Zeus, a 12-year-old German Shepherd, showed complete remission of terminal cancer, while Benson, a 12-year-old Newfoundland suffering from severe arthritis, regained his mobility, leading to what caretakers described as a miraculous recovery.
Erez Aminov, the newly appointed Chairman CEO of Telomir Pharmaceuticals, expressed his commitment to advancing the science behind Telomir-1 and accelerating its path to market.
"The results seen in this study are a testament to the groundbreaking potential of Telomir-1. Our focus is on ensuring that we continue to push forward with the rigorous scientific research necessary to bring this promising treatment into human trials for particular indications, through the regulatory process and to ultimately to market as quickly and safely as possible. At Telomir, we are committed to transforming the future of longevity science, and these early findings bring us one step closer to achieving that goal," said Aminov.
Dr. Michael Roizen added, "The preliminary results we're seeing with Telomir-1 are very encouraging. By lengthening telomeres, we believe Telomir-1 can promote cell regeneration and potentially reverse several aspects of aging or age-related conditions. I'm excited to continue working with Telomir to explore the full potential of this innovative therapy."
To watch the full ABC7 exclusive segment, please visit: https://www.mysuncoast.com/2024/08/16/abc7-exclusive-new-study-reveals-promising-results-age-reversal-pill-dogs/
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in longevity science in both humans and dogs. The Company is focused on the development of Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. The Company's goal is to explore the potential of Telomir-1 starting with ongoing research in animals and then in humans.
Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop, gain regulatory approval for and commercialize Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.
The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.
Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.
Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding (i) the anticipated benefits of the compassion use program described herein, (ii) anticipated timelines for preclinical and clinical testing of Telomir-1 and (iii) the potential therapeutic benefits of Telomir-1 generally.
Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of significant risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Readers are cautioned that the statements made by third parties in the news story linked in this release represent the views of such third parties and not necessarily the views of Telomir Pharmaceuticals.
Contact Information
Helga Moya
info@telomirpharma.com
(813) 864-2558
SOURCE: Telomir Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What is Telomir-1 and how does it work?
What were the results of Telomir-1 in the dog study featured on ABC?
When will Telomir-1 (TELO) be available for human use?
Who is involved in the development of Telomir-1 (TELO)?
